Burning Rock’s revenue dips on weakness in R&D, central lab businesses
Cancer testing company Burning Rock Biotech Ltd. (BNR.US) on Thursday reported its revenue fell 9.3% year-on-year to 135 million yuan ($20.1 million) in the second quarter, as an increase for…
Following Rough Year, Is Burning Rock Set to Turn the Corner?
Cancer testing specialist expects sharply slower growth this year than previous guidance due to Covid-related travel restrictions Key Takeaways: Burning Rock expects fourth-quarter revenue to grow just 6% year-on-year due…
RELATED ARTICLES
-
GreenTree revenue falls on weakness in hotel, restaurant businesses
- Chinese ‘Easter Eggs’ fall back to earth after wild year on Wall Street
-
BRIEF: Hello Group’s booming offshore business fails to offset weakness at home
MOMO.US
- PDD trades rock-bottom prices for sustainability as old growth engine stalls
- Angelalign finds new smile in central procurement era
- BRIEF: Atour’s revenue jumps on momentum for retail, hotel management businesses
-
Central China Securities first-half profit rises more than 46%
1375.HK
